Literature DB >> 19404716

Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients.

Santiago Perez-Lloret1, Malco Rossi, María Inés Nouzeilles, Claudia Trenkwalder, Daniel P Cardinali, Marcelo Merello.   

Abstract

The aim of this study was to compare the results of the day-to-day self-evaluation of sleep quality by sleep logs with Parkinson's disease sleep scale (PDSS) in Parkinson's disease (PD) patients. Actigraphy was used as an independent analysis of nighttime activity interfering with sleep. A total of 71 idiopathic PD patients and 21 age- and sex-matched normal individuals lacking any type of sleep disturbance were recruited. Sleep was evaluated by PDSS, 7-d sleep log and actigraphy. Sleep logs and PDSS showed reduced sleep quality and daytime somnolence scores in moderate/severe PD patients as compared to healthy controls. Significant correlations were found between sleep quality in sleep logs and all domains of PDSS sleep quality, except for the presence of nocturia, which correlated with nocturnal activity. PD severity and depression were the only predictors of reduced sleep quality. The retrospective and day-to-day sleep self-evaluations were coincident. Reduced sleep quality was related to increased PD severity and depression scores.

Entities:  

Mesh:

Year:  2009        PMID: 19404716      PMCID: PMC3085768          DOI: 10.1007/s00415-009-5141-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


Introduction

Up to 90% of Parkinson’s disease (PD) patients complain of sleep problems [11, 14, 24]. The most commonly observed sleep disorders in PD patients are linked to nocturnal motor disorder, including off-state dystonia, cramps, tremor, or severe akinesia and rigidity producing painful postures and problems when turning in bed as well as neuropsychiatric symptoms, i.e., vivid dreams, nocturnal hallucinations, and REM sleep behavior disorder [3, 6, 12]. Periodic limb movements disorder and nocturia are also commonly observed in PD [3, 7, 12]. The 15-item Parkinson’s disease sleep scale (PDSS) has been developed for retrospective sleep self-evaluation in PD [3, 17]. The scale is reliable, is able to differentiate healthy controls from PD patients, and correlates well with disease severity. The daytime somnolence item (#15) and restlessness item (#4) have received support from the Epworth score [3] and International Restless Legs Syndrome Study Group diagnostic criteria [25], respectively. One of its limitations is that it is based on 15-d retrospective sleep quality self-evaluation. On the other hand, sleep logs allow a day-to-day evaluation of bedtime, rising time, sleep latency, number and duration of awakenings, naps, and some indexes of sleep quality [23]. Though sleep logs are widely used for sleep evaluation in healthy subjects and insomniacs [4, 21, 23], they have not been systematically assessed in PD. In the present study, the day-to-day sleep quality self-evaluation by sleep log was compared to PDSS results. Actigraphy was used as an independent analysis of nighttime activity interfering with sleep.

Methods

Study sample

PD patients were recruited from a tertiary out-patient clinic. To be included, subjects had to fulfill the United Kingdom Parkinson’s Disease Society Brain Bank criteria [16] and have a mini-mental state examination (MMSE) score >24 points. A group of healthy controls frequency-matched for sex and age, without sleep complaints, chronic diseases or secondary causes of insomnia, and not taking any type of hypnotic medication, were recruited from the general population. The protocol conforms to the principles enumerated in the Helsinki Declaration, was approved by the Institutional Review Board, and all subjects signed an informed consent after full explanation of the procedures.

PD evaluation

PD patients were subjected to cognitive, psychiatric, and motor evaluation including the MMSE [10], Montgomery-Asberg Depression Rating scale (MADRS) [20], Unified PD rating scale (UPDRS) [9], and Hoehn & Yahr scale (H&Y) [15]. Medication records were used to calculated levodopa equivalent daily dose (LDED) according to the usual formula [22].

PDSS

PD patients and healthy controls completed the self-administered Spanish version of PDSS during their clinical interviews [17]. For evaluation of the results, PDSS items were grouped according to domain: sleep quality (items 1–3); nocturnal restlessness (items 4 and 5); nocturnal psychosis (items 6 and 7), nocturia (item 8); nocturnal motor symptoms (items 9–13) and daytime somnolence (items 14 and 15) [25].

Sleep diary and actigraphy

After the initial clinical interview, a standard sleep log was completed by patients and controls every day after waking up. Information about the time at which subjects fell asleep and woke up, as well as the number and duration of perceived awakenings were registered [1, 2]. It also included three 10 cm visual analog scales for quantification of sleep latency (“a lot”–“a little”), sleep quality (“bad”–“good”) and morning freshness (i.e., how tired the subject felt on waking, “a lot”–“a little”). Total sleep log scores were calculated as the sum of all three items, ranging between 0 and 30. Participants were instructed to wear an actigraphy device (MicroMini-Motionlogger, Ambulatory Monitoring Inc, NY, USA) in addition to completing the 7-d sleep log. The actigraphic device was attached to the non-dominant wrist [18]. Nocturnal activity, nocturnal motility time, and time in bed were calculated using Action W 2.5 software (Ambulatory Monitoring Inc, NY, USA).

Statistical analysis

Categorical data were compared using chi-square, and numerical variables by ANOVA. Factor analysis was used to check the reliability of the sleep logs. The Pearson correlation coefficient was employed to assess the associations between PDSS, sleep log, and actigraphy. Sleep log scores and nocturnal activity were related to the characteristics of PD and its treatment by multiple linear regression. Actigraphic data were log transformed to render them normally distributed. Data are expressed as mean ± standard error of the mean unless otherwise stated. Alfa error was set at 0.05.

Results

A total of 71 PD patients and 25 age- and sex-matched controls were recruited. Four controls were excluded because of incomplete data. Age was 64.4 ± 2.0 years in controls and 68.5 ± 1.0 years in PD patients (p = 0.1). No gender differences were noticed between controls and patients (29 and 49% were males, respectively, p = 0.1). PD patients showed UPDRS II scores (daily living), III (motor score), and IV (levodopa complication scores) of 11.4 ± 0.8, 17.8 ± 1.2, 2.9 ± 0.5, respectively. The sum of these scores (UPDRS II–IV) was 32.0 ± 1.9. Median Hoehn & Yahr score was 2 (interquartile range 1.5–3). Mean disease duration was 7.7 ± 0.7 years and mean MMSE and MADRS scores were 29.1 ± 0.2 and 7.0 ± 0.8, respectively. Out of the 71 PD patients, 14 were medication-naïve (20%). In treated subjects, mean LDED was 596.9 ± 54.9 mg/d. Fifteen (21%) patients received only levodopa, while 14 (20%), 13 (18%), 10 (14%), and 5 (7%) patients received also piribedil, cabergoline, pramipexol, or other dopaminergic agonists, respectively.

Sleep evaluation in PD patients

As summarized in Table 1, sleep quality was significantly worse in PD patients as compared to controls when evaluated either by PDSS or by sleep log. While advanced PD patients (H&Y III–V) showed striking sleep disturbance, mild/moderate PD patients (H&Y I–II) showed less sleep deterioration, reaching significance only in PDSS sleep quality, daytime somnolence, and PDSS total score.
Table 1

Comparison of sleep log and actigraphic data between PD patients and controls

Controls (n = 21)H&Y I–II (n = 46)H&Y III–V (n = 25)p
PDSS
 Sleep quality22.69 ± 1.0919.8 ± 0.85*18.46 ± 1.23*0.05
 Nocturnal restlessness16.43 ± 0.4215.8 ± 0.4514.83 ± 0.720.2
 Nocturnal psychosis17.81 ± 0.516.27 ± 0.4814.24 ± 0.84*0.002a
 Nocturia4.69 ± 0.713.74 ± 0.494.55 ± 0.70.5
 Nocturnal motor symptoms44.65 ± 0.6642.02 ± 0.9338.37 ± 1.72*<0.01a
 Daytime somnolence16.51 ± 0.3714.13 ± 0.6*11.99 ± 0.93*<0.001a
 PDSS total score122.78 ± 1.77111.78 ± 2.38*102.43 ± 3.71*<0.001a
Sleep log
 Sleep latency1.93 ± 0.391.99 ± 0.212.22 ± 0.280.8
 Sleep quality7.5 ± 0.376.87 ± 0.255.89 ± 0.23*0.003a
 Morning alertness7.29 ± 0.436.99 ± 0.246.15 ± 0.380.08
 Total sleep log score22.41 ± 0.9121.86 ± 0.5619.82 ± 0.56*0.03
 Awakenings number1.31 ± 0.241.57 ± 0.141.82 ± 0.140.2
 Awakening time (min)19.75 ± 4.6626.14 ± 4.4738.92 ± 6.730.8
 Nap time (min)20.29 ± 7.0634.71 ± 4.5447.3 ± 6.69*0.02
Actigraphy
 Nocturnal activity (counts)732.53 ± 76.73887.41 ± 77.531029.64 ± 179.530.5
 Nocturnal motility time (min)30.69 ± 4.7735.3 ± 3.5638.47 ± 6.90.6
 Time in bed (min)458.34 ± 15.73421.67 ± 8.33415.12 ± 11.710.04

PDSS total score is the sum of all its domains. Sleep log total score is obtained as: sleep quality + morning alertness + (10 − sleep latency)

* p < 0.05 versus controls (ANOVA followed by Dunnett’s post-hoc test)

aBrown–Forsythe adjustment for unequal variances was employed

Comparison of sleep log and actigraphic data between PD patients and controls PDSS total score is the sum of all its domains. Sleep log total score is obtained as: sleep quality + morning alertness + (10 − sleep latency) * p < 0.05 versus controls (ANOVA followed by Dunnett’s post-hoc test) aBrown–Forsythe adjustment for unequal variances was employed

Comparison of historical sleep data provided by PDSS with day-to-day assessment by sleep log and actigraphy

Significant correlations between PDSS and sleep log were found (Table 2). As can be seen, in general, sleep log quality scores correlated with all PDSS subdomains, except for Nocturia, which correlated only with increased awakening numbers, reduced morning alertness, and higher nocturnal activity.
Table 2

Relationships between PDSS, sleep log, and actigraphy in PD patients

Sleep logActigraphy
PDSS domainsSleep latencySleep qualityMorning alertnessTotal scoreAwakenings numberAwakenings timeNocturnal motility time
Sleep qualityr = −0.31 (p < 0.01)r = 0.50 (p < 0.01)r = 0.41 (p < 0.01)r = 0.59 (p < 0.01)r = −0.14 (p = 0.2)r = −0.33 (p < 0.01)r = −0.10 (p = 0.36)
Nocturnal restlessnessr = −0.14 (p = 0.9)r = 0.43 (p < 0.01)r = 0.32 (p < 0.01)r = 0.31 (p < 0.01)r = 0.02 (p < 0.9)r = −0.29 (p < 0.01)r = −0.08 (p < 0.7)
Nocturnal psychosisr = −0.16 (p < 0.5)r = 0.21 (p < 0.05)r = 0.24 (p < 0.04)r = 0.25 (p < 0.01)r = 0.06 (p < 0.9)r = −0.27 (p < 0.01)r = −0.20 (p < 0.07)
Nocturiar = −0.03 (p < 0.6)r = 0.03 (p < 0.9)r = −0.31 (p < 0.01)r = −0.1 (p < 0.2)r = −0.28 (p < 0.04)r = 0.03 (p < 0.9)r = −0.30 (p < 0.01)
Nocturnal motor symptomsr = −0.15 (p < 0.4)r = 0.48 (p < 0.01)r = 0.56 (p < 0.001)r = 0.50 (p < 0.01)r = 0.05 (p < 0.8)r = −0.39 (p < 0.01)r = −0.03 (p < 0.8)
Diurnal somnolencer = −0.10 (p < 0.5)r = 0.26 (p < 0.03)r = 0.28 (p < 0.02)r = 0.30 (p < 0.01)r = −0.11 (p < 0.3)r = −0.12 (p < 0.2)r = −0.10 (p < 0.5)

Data was analyzed by Pearson methods. Actigraphic variables were log transformed

Relationships between PDSS, sleep log, and actigraphy in PD patients Data was analyzed by Pearson methods. Actigraphic variables were log transformed The internal consistency of sleep logs sleep quality indicators were evaluated by factor analysis. Only one factor including sleep latency, sleep quality, and morning alertness, explaining 60% of total variance, could be found. A multiple regression analysis showed that, on one hand, sleep log total score was independently related to H&Y score (r = −0.25, p = 0.05) and MADRS score (r = −0.24, p = 0.05). On the other hand, nocturnal activity correlated with LDED (r = −0.40, p = 0.02) and MMSE score (r = −0.25, p = 0.05).

Discussion

In the present study, day-to-day sleep assessment by sleep logs was compared to PDSS retrospective sleep evaluation. The foregoing results indicate that daily evaluations of sleep quality by sleep log correlated significantly with most PDSS subdomains, suggesting that both tools can evaluate sleep quality to a similar extent. Moreover, sleep quality evaluated by sleep logs was related to disease severity and depression in PD, which coincides with previous reports [3, 11, 25]. The main limitation of this study is that polysomnography (PSG) was not used as the reference method for sleep evaluation. Nonetheless, the significant divergence between PSG and subjective sleep evaluation observed in PD [13] as well as the result that subjective more than objective findings of impaired sleep quality impact negatively on quality of life [19] suggest that PSG may not be the best method against which subjective sleep evaluation tools should be compared. Many questions on the sleep log and PDSS are similar, providing the basis for the results herein observed. Nonetheless, while the PDSS retrospectively assesses sleep quality in 15 days constituting a simple bedside screening of sleep disturbances in PD, the degree of detail provided by the sleep logs make them suitable for analysis of particular cases or for clinical interventional studies. Actigraphy is a common companion to the sleep log [4, 21, 23]. Its use in PD sleep studies [5, 8] has been questioned mainly because it may not be accurate enough to discern sleep state from PD-related immobility or tremor [12], which was confirmed in our study. In summary, retrospective sleep quality evaluation by the PDSS and day-to-day evaluation by sleep log coincided. While PDSS can be used as a simple bedside sleep disturbances screening tool, sleep logs are suitable for analysis of particular cases or for clinical interventional studies. On the other hand, while utility of actigraphy for nocturnal activity measurement is warranted, its role in sleep evaluation in PD appears to be very limited.
  24 in total

1.  The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease.

Authors:  K R Chaudhuri; S Pal; A DiMarco; C Whately-Smith; K Bridgman; R Mathew; F R Pezzela; A Forbes; B Högl; C Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly.

Authors:  Daniel P Cardinali; Elisa Gvozdenovich; Marcos R Kaplan; Isidoro Fainstein; Hugo A Shifis; Santiago Pérez Lloret; Liliana Albornoz; Armando Negri
Journal:  Neuro Endocrinol Lett       Date:  2002-02       Impact factor: 0.765

Review 3.  Evaluation of chronic insomnia. An American Academy of Sleep Medicine review.

Authors:  M J Sateia; K Doghramji; P J Hauri; C M Morin
Journal:  Sleep       Date:  2000-03-15       Impact factor: 5.849

4.  Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine.

Authors:  A Chesson; K Hartse; W M Anderson; D Davila; S Johnson; M Littner; M Wise; J Rafecas
Journal:  Sleep       Date:  2000-03-15       Impact factor: 5.849

Review 5.  Parkinson's disease and sleep.

Authors:  Diego Garcia-Borreguero; Oscar Larrosa; Mauricio Bravo
Journal:  Sleep Med Rev       Date:  2003-04       Impact factor: 11.609

Review 6.  Sleep dysfunction in Parkinson's disease.

Authors:  C Trenkwalder
Journal:  Clin Neurosci       Date:  1998

7.  The association between disease severity and sleep-related problems in patients with Parkinson's disease.

Authors:  Svenja Happe; Peter Lüdemann; Klaus Berger
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

8.  Accuracy of sleep perceptions among insomnia sufferers and normal sleepers.

Authors:  Melanie K Means; Jack D Edinger; D Michael Glenn; Ana I Fins
Journal:  Sleep Med       Date:  2003-07       Impact factor: 3.492

9.  Parkinson's Disease Sleep Scale: validation study of a Spanish version.

Authors:  Pablo Martínez-Martín; Carlos Salvador; Luis Menéndez-Guisasola; Sonia González; Aurelio Tobías; Javier Almazán; K Ray Chaudhuri
Journal:  Mov Disord       Date:  2004-10       Impact factor: 10.338

10.  Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.

Authors:  Ajmal Razmy; Anthony E Lang; Colin M Shapiro
Journal:  Arch Neurol       Date:  2004-01
View more
  12 in total

Review 1.  Parkinson's disease and 2009: recent advances.

Authors:  David P Breen; Roger A Barker
Journal:  J Neurol       Date:  2010-04-08       Impact factor: 4.849

2.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

3.  The impact of sleep and mood disorders on quality of life in Parkinson's disease patients.

Authors:  Eva Havlikova; Jitse P van Dijk; Iveta Nagyova; Jaroslav Rosenberger; Berrie Middel; Tatiana Dubayova; Zuzana Gdovinova; Johan W Groothoff
Journal:  J Neurol       Date:  2011-05-26       Impact factor: 4.849

4.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

5.  A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans.

Authors:  Elisabet Ortiz-Tudela; Antonio Martinez-Nicolas; Manuel Campos; María Ángeles Rol; Juan Antonio Madrid
Journal:  PLoS Comput Biol       Date:  2010-11-11       Impact factor: 4.475

6.  Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study.

Authors:  Santiago Perez Lloret; Malco Rossi; Marcelo Merello; Olivier Rascol; Daniel P Cardinali
Journal:  Parkinsons Dis       Date:  2011-05-24

7.  Fatigue is associated with the onset of hallucinations in patients with Parkinson's disease: A 3-year prospective study.

Authors:  Masanori Ikeda; Hiroshi Kataoka; Satoshi Ueno
Journal:  eNeurologicalSci       Date:  2016-04-16

8.  Quality of sleep in patients with Parkinson's disease.

Authors:  Mohammad Reza Najafi; Ahmad Chitsaz; Zahra Askarian; Mohammad Amin Najafi
Journal:  Int J Prev Med       Date:  2013-05

9.  Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson's disease.

Authors:  Samuel J Bolitho; Sharon L Naismith; Pierre Salahuddin; Zoe Terpening; Ron R Grunstein; Simon J G Lewis
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version.

Authors:  Krisztina Horváth; Zsuzsanna Aschermann; Péter Ács; Gabriella Deli; József Janszky; Sámuel Komoly; Kázmér Karádi; Márton Kovács; Attila Makkos; Béla Faludi; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2015-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.